Hockey Australia partnership expands Impression Healthcare reach to more than 1 million


Published 24-JAN-2017 15:32 P.M.


2 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.

Click Here to View Latest Articles

Impression Healthcare (ASX:IHL) has taken its total partnership marketing reach to more than 1 million grassroots sporting club members and participants following the announcement on Tuesday that it has partnered with national sports body, Hockey Australia, extending its customer marketing access by an additional 90,000 hockey players across Australia.

This agreement builds on the group’s Gameday operation’s existing Hockey New South Wales, Hockey Victoria and Hockey Western Australia partnerships.

As a backdrop, Impression Healthcare offers Gameday Mouthguards as its first product offering, with additional products planned for marketing. The product makes traditionally expensive custom mouthguards accessible to everyday Australians by providing a convenient, online, end to end process by which customers can take their own dental impressions at home and receive a superior custom fit product.

Impression Healthcare’s Chief Executive, Matt Weston, highlighted on Tuesday that hockey is a fast, high contact sport which demands the appropriate protective gear, perhaps pointing towards its potential for the rollout of other protective products in line with the group’s business strategy.

Hockey Australia targeting 250,000 participants by 2020

Assessing the scalability of the Hockey Australia deal, the national body is targeting 250,000 registered hockey participants by 2020.

However it is unclear how many of these participants IHL will be able to convert, and as a company still in its early stages, investors should seek professional financial advice before making an investment decision.

The two-year agreement currently provides Gameday with direct marketing access to Hockey Australia’s 160,000 participants to directly market and promote its mouthguards nationwide with over 70,000 of these participants already accessed via existing relationships.

Potential upside from the existing agreement is the possible introduction to international hockey governing bodies of six countries which could incorporate a range of promotional opportunities from social media campaigns to signage at international tournaments.

General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.


Discover Small Cap
Biotech Stocks

Join thousands of other Investors following our stock commentary for Free